Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants.

نویسندگان

  • Timolaos Rizos
  • Christian Herweh
  • Ekkehart Jenetzky
  • Christoph Lichy
  • Peter Arthur Ringleb
  • Werner Hacke
  • Roland Veltkamp
چکیده

BACKGROUND AND PURPOSE Thrombolysis in patients using oral anticoagulants (OAC) and in patients for whom information on OAC status is not available is frequently delayed because the standard coagulation analysis procedure in central laboratories (CL) is time-consuming. By using point-of-care (POC) coagumeters, international normalized ratio (INR) values can be measured immediately at the bedside. The accuracy and effectiveness of POC devices for emergency management in acute ischemic stroke has not been tested. METHODS In phase 1, the reliability of emergency INR POC measurements in comparison to CL was determined. In phase 2, patients with ischemic stroke admitted within the time frame for systemic thrombolysis and who were either using OAC or for whom information on OAC status was not available were enrolled. Patients received thrombolysis if POC INR was <or=1.5. Precision and time gain was recorded for INR as measured by POC vs CL. RESULTS In phase 1 (n=113), Bland-Altman analysis showed close agreement between POC and CL, and Pearson correlation was highly significant (r=0.98; P<0.01). In phase 2, 48 patients were included, of whom 70.8% were using OAC; 23 patients received thrombolysis. After subtracting the time needed for the diagnostic work-up, the net time gain was 28+/-12 minutes (mean+/-SD). CONCLUSIONS Measuring INR by POC in an emergency setting is sufficiently precise in OAC acute stroke patients and substantially reduces the time interval until INR values are available and therefore may hasten the initiation of thrombolysis.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Coagulation Testing in Acute Ischemic Stroke Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.

BACKGROUND AND PURPOSE In patients who present with acute ischemic stroke while on treatment with non-vitamin K antagonist oral anticoagulants (NOACs), coagulation testing is necessary to confirm the eligibility for thrombolytic therapy. We evaluated the current use of coagulation testing in routine clinical practice in patients who were on NOAC treatment at the time of acute ischemic stroke. ...

متن کامل

Potential impact of point-of-care INR testing on intravenous thrombolysis.

Correspondence: Adriana Bastos Conforto; Rua Galeno de Almeida, 207 apto 23; 05410-030 São Paulo SP, Brasil; E-mail: [email protected] Conflict of intereste: There is no conflict of interest to declare. Received 01 June 2014 Accepted 09 June 2014 In this issue of Arquivos de Neuro-psiquiatria, Bruch et al. compared international normalized ratio (INR) measurements performed with point-...

متن کامل

Accidental Thrombolysis in a Stroke Patient Receiving Apixaban

Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) is contraindicated in stroke patients receiving oral anticoagulants [1] . Knowledge of current medication is therefore necessary before commencing IVT. In the emergency setting, pointof-care (POC) coagulation devices provide rapid international normalized ratio (INR) measurements [2] . However, current POC devi...

متن کامل

Thrombolysis in stroke patients: Comparability of point-of-care versus central laboratory international normalized ratio

BACKGROUND In acute stroke patients, thrombolysis is one gold standard therapy option within the first four hours after the ischemic event. A contraindication for thrombolysis is an International Normalized Ratio (INR) value >1.7. Since time is brain, rapid and reliable INR results are fundamental. Aim was to compare INR values determined by central laboratory (CL) analyzer and Point-of-Care Te...

متن کامل

Management of acute stroke in patients taking novel oral anticoagulants

Each year, 1·0-2·0% of individuals with atrial fibrillation and 0·1-0·2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0·2-0·5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Stroke

دوره 40 11  شماره 

صفحات  -

تاریخ انتشار 2009